the risk for DVT recurrence.
The use of IVC filters has dramatically escalated over the past two decades, from two to more than 10 per 100 patients with PE. 2 In addition, many more filter models are available. The indications for filter use have also broadened to include patients at high risk for death from PE due to severe existing pulmonary disease or cancer and primary prevention in high-risk situations such as trauma or complex surgical procedures; 3 however, much of this use is not evidence-based. In one of the few randomized, controlled clinical trials, 400 patients with proximal DVT-complicating cancer were randomized to filter or no-filter groups. 4 All received standard anticoagulant therapy. There was a statistically significant decrease in PE in the filter group during the first 12 days of the trial (two versus nine), but the recurrence rate for DVT at two years was significantly increased in the filter group (37 versus 21) and there was no difference in mortality (43 versus 40). On eight-year follow-up, the differences in rates of PE (favoring the filter group, hazard ratio 0.37) and DVT (favoring the no-filter group, hazard ratio 1.52) persisted, and there was no difference in survival. 5 A retrospective review confirmed that the use of filters in addition to standard therapeutic anticoagulation failed to lower the incidence of subsequent venous thrombotic events.
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A population-based study of patients with discharge diagnoses of venous thromboembolism showed that the DVT recurrence rate was increased (relative risk 1.8) following filter placement. 7 Furthermore, those with filters did not have a significant reduction in subsequent re-hospitalizations for PE, and DVT recurrence rates were higher in those with filters initially placed because of PE (hazard ratio 2.6). 8 The studies listed above have tempered enthusiasm for filter placement.
Problems with the use of IVC filters include device failure, characterized by recurrent PE despite the presence of the filter. This may be due to tilting or too small a filter for the diameter of the vena cava, development of collateral circulation around the filter, and formation of thrombi above the filter. Other hazards of filter placement are vena cava thrombosis or perforation, 9 thrombosis at the venous access site, and embolization of the filter to the heart or lungs. Inexperienced operators may also place the filter in an ectopic position, even in the abdominal aorta. Additionally, the costs associated with filter placement are not insignificant. Temporary vena cava filters are indicated in patients with contraindications to anticoagulation, usually a major risk for bleeding, and for protection from PE during thrombolytic therapy for lower-extremity or pelvic DVT. These filters are usually removed within three weeks of placement, but there are reports of retrieval from 30 to 300 days after implantation. 11 Some trauma surgeons also recommend the placement of a temporary filter in patients with major trauma who are thought to be at high risk for development of venous thrombo-embolism. 12 Unfortunately, randomized trials are few, and retrospective reviews of experience with such patients suggest no difference in the incidence of PE 13, 14 or death.
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In fact, the current Consensus Conference of the American College of Chest Physicians specifically recommends against the use of an IVC filter for thromboprophylaxis. 16 The authors reason that there is a lack of any direct evidence of efficacy, uncertainty about which patients might benefit, and the procedure is high-cost. They note that most temporary filters are placed about six days after injury, at a time when it is generally safe to administer prophylactic doses of anticoagulants that would provide adequate protection against thrombosis. They also note that a second procedure, entailing radiation exposure and instrumentation, is required to remove the filter. They emphasize that until there is convincing evidence to the contrary, filters should be placed only in patients with proven proximal DVT and either an absolute contraindication to full-dose anticoagulation or a need for urgent major surgery.
The following case studies from the author's files demonstrate the use of filters and some of the complications associated with their placement.
A 78-year-old man had a mesenteric venous thrombosis at 56 years of age and was found to have protein S deficiency. Shortly thereafter, his nephew presented with recurrent DVT and was also found to have protein S deficiency. The propositus was treated with warfarin and was fully compliant with therapy, and the international normalized ratios were consistently within the therapeutic range. [2] [3] However, he began having bilateral leg swelling, became short of breath, and a right pleural effusion was discovered. Further evaluation revealed pulmonary hypertension, presumably secondary to silent PE. An IVC filter was placed and he was continued on warfarin. The indication for filter placement in this patient was failure of therapeutic oral anticoagulation to prevent recurrent PE.
A 46-year-old man with hereditary hemorrhagic telangiectasia and recurrent bleeding from the nose and gastrointestinal (GI) tract developed a left popliteal vein thrombosis when hospitalized for bleeding. A heparin infusion was started, but he had severe epistaxis and the anticoagulant was discontinued. An IVC filter was placed.
Subsequently, he had a right common femoral vein thrombosis and continues to have nose and GI bleeding. The precipitating factor for the left leg DVT was probably bed-rest, but the inciting factor for the right leg DVT might have been the IVC filter.
A 56-year-old man fell from a ladder, sustaining a laceration of the right kidney, right rib fractures, and a fractured right radius. A cast was placed and he was discharged, but returned two weeks later with leftsided chest pain, found to be due to a PE. Due to fears that he might 
